RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.
Zacks
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Zacks
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure, while reaffirming 2026 guidance and advancing acquisitions.
Zacks
HALO Inks Deal With INCY to Support Cancer Therapy Development
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
Zacks
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
Zacks
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
Zacks
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Zacks
Reasons Why Investors Should Consider Betting on PTC Stock Now
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
Zacks
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.